|
|
| | PF-06650833 Basic information |
| Product Name: | PF-06650833 | | Synonyms: | PF-06650833;1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide;6-Isoquinolinecarboxamide,1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-2-pyrrolidinyl)methoxy)-7-methoxy-;PF06650833;PF 06650833;CS-2457;1-[[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxo-2-pyrrolidinyl]methoxy]-7-methoxy-6-isoquinolinecarboxamide;PF06650833 >=98% (HPLC);PF06650883 | | CAS: | 1817626-54-2 | | MF: | C18H20FN3O4 | | MW: | 361.37 | | EINECS: | | | Product Categories: | API | | Mol File: | 1817626-54-2.mol |  |
| | PF-06650833 Chemical Properties |
| Boiling point | 621.0±55.0 °C(Predicted) | | density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO : ≥ 33 mg/mL (91.32 mM) | | form | powder | | pka | 13.44±0.70(Predicted) | | color | white to beige | | InChIKey | JKDGKIBAOAFRPJ-ZBINZKHDSA-N | | SMILES | C1(OC[C@@H]2[C@H](CC)[C@H](F)C(=O)N2)C2=C(C=C(C(N)=O)C(OC)=C2)C=CN=1 |
| | PF-06650833 Usage And Synthesis |
| Uses | Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas[1][2]. | | Biochem/physiol Actions | PF06650833 has been studied for its use in the treatment of Waldenstrom macroglobulinemia, indicated by overproduction of IgM (immunoglobulin M)-producing lymphoplasmacytic cells. | | in vivo | Zimlovisertib (0.3-30 mg/kg; oral administration; for 2.5 hours; male Sprague-Dawley rats) treatment significantly inhibits LPS-induced TNF-α in a dose dependent manner. Mean exposures of Zimlovisertib in plasma are 2.1 nM, 7.7 nM, 19 nM and 150 nM free, respectively, at 2.5 hours after oral administration of Zimlovisertib at 0.3, 1, 3, and 30 mg/kg. The fraction unbound in rat plasma of Zimlovisertib is 0.3[1]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.1 mg/kg, 1 mg/kg, 3 mg/kg, 30 mg/kg | | Administration: | Oral administration; for 2.5 hours | | Result: | Significantly inhibited LPS-induced TNF-α in a dose dependent manner.
|
| | IC 50 | IRAK4: .2 nM (IC50) | | storage | Store at -20°C | | References | [1] Lee KL, et al. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13;60(13):5521-5542. DOI:10.1021/acs.jmedchem.7b00231
[2] Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015). Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DOI:10.1080/13543776.2016.1202926 |
| | PF-06650833 Preparation Products And Raw materials |
|